|
1
|
Al-Samkari H and Berliner N:
Hemophagocytic lymphohistiocytosis. Annu Rev Pathol. 13:27–49.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yildiz H, Van Den Neste E, Defour JP,
Danse E and Yombi JC: Adult haemophagocytic lymphohistiocytosis: A
review. QJM. Jan 14–2020.(Epub ahead of print). PubMed/NCBI
|
|
3
|
Jordan MB, Allen CE, Greenberg J, Henry M,
Hermiston ML, Kumar A, Hines M, Eckstein O, Ladisch S, Nichols KE,
et al: Challenges in the diagnosis of hemophagocytic
lymphohistiocytosis: Recommendations from the North American
consortium for histiocytosis (NACHO). Pediatr Blood Cancer.
66:e279292019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Henter JI, Horne A, Aricó M, Egeler RM,
Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski
J and Janka G: HLH-2004: Diagnostic and therapeutic guidelines for
hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer.
48:124–131. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang J, Huang J and Zeng Q: Network
meta-analysis of targeted therapies for diffuse large B cell
lymphoma. BMC Cancer. 20:12182020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sarkozy C and Sehn LH: Management of
relapsed/refractory DLBCL. Best Pract Res Clin Haematol.
31:209–216. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wilson WH, Young RM, Schmitz R, Yang Y,
Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano
J, et al: Targeting B cell receptor signaling with ibrutinib in
diffuse large B cell lymphoma. Nat Med. 21:922–926. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Thieblemont C, Tilly H, Gomes da Silva M,
Casasnovas RO, Fruchart C, Morschhauser F, Haioun C, Lazarovici J,
Grosicka A, Perrot A, et al: Lenalidomide maintenance compared with
placebo in responding elderly patients with diffuse large b-cell
lymphoma treated with first-line rituximab plus cyclophosphamide,
doxorubicin, vincristine, and prednisone. J Clin Oncol.
35:2473–2481. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Younes A, Sehn LH, Johnson P, Zinzani PL,
Hong X, Zhu J, Patti C, Belada D, Samoilova O, Suh C, et al:
Randomized phase III trial of ibrutinib and rituximab plus
cyclophosphamide, doxorubicin, vincristine, and prednisone in
non-germinal center B-cell diffuse large B-cell lymphoma. J Clin
Oncol. 37:1285–1295. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Denker S, Bittner A, Na IK, Kase J, Frick
M, Anagnostopoulos I, Hummel M and Schmitt CA: A phase I/II
first-line study of R-CHOP plus B-cell
receptor/NF-κB-double-targeting to molecularly assess therapy
response. Int J Hematol Oncol. 8:IJH202019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wilson WH, Wright GW, Huang DW, Hodkinson
B, Balasubramanian S, Fan Y, Vermeulen J, Shreeve M and Staudt LM:
Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of
DLBCL. Cancer Cell. 39:1643–1653.e3. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Henter JI, Aricò M, Egeler RM, Elinder G,
Favara BE, Filipovich AH, Gadner H, Imashuku S, Janka-Schaub G,
Komp D, et al: HLH-94: A treatment protocol for hemophagocytic
lymphohistiocytosis. HLH study GRoup of the histiocyte society. Med
Pediatr Oncol. 28:342–347. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hans CP, Weisenburger DD, Greiner TC,
Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E,
Braziel RM, Jaffe ES, et al: Confirmation of the molecular
classification of diffuse large B-cell lymphoma by
immunohistochemistry using a tissue microarray. Blood. 103:275–282.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fonseca R, Bergsagel PL, Drach J,
Shaughnessy J, Gutierrez N, Stewart AK, Morgan G, Van Ness B, Chesi
M, Minvielle S, et al: International myeloma working group
molecular classification of multiple myeloma: Spotlight review.
Leukemia. 23:2210–2221. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yohe S and Thyagarajan B: Review of
clinical next-generation sequencing. Arch Pathol Lab Med.
141:1544–1557. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bartlett NL, Wilson WH, Jung SH, His ED,
Maurer MJ, Pederson LD, Polley MC, Pitcher BN, Cheson BD, Kahl BS,
et al: Dose-adjusted EPOCH-R compared with R-CHOP as frontline
therapy for diffuse large B-cell lymphoma: Clinical outcomes of the
phase III intergroup trial alliance/CALGB 50303. J Clin Oncol.
37:1790–1799. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Daudignon A, Quilichini B, Ameye G, Poirel
H, Bastard C and Terré C: Cytogenetics in the management of
multiple myeloma: An update by the groupe francophone de
cytogénétique hématologique (GFCH). Ann Biol Clin (Paris).
74:588–595. 2016.PubMed/NCBI
|
|
18
|
Tian E: Fluorescence in situ hybridization
(FISH) in multiple myeloma. Methods Mol Biol. 1792:55–69. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Campo M and Berliner N: Hemophagocytic
lymphohistiocytosis in adults. Hematol Oncol Clin North Am.
29:915–925. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
La Rosee P, Horne A, Hines M, von Bahr
Greenwood T, Machowicz R, Berliner N, Birndt S, Gil-Herrera J,
Girschikofsky M, Jordan MB, et al: Recommendations for the
management of hemophagocytic lymphohistiocytosis in adults. Blood.
133:2465–2477. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chang Y, Cui M, Fu X, Han L, Zhang L, Li
L, Li X, Sun Z, Wu J, Zhang X, et al: Lymphoma associated
hemophagocytic syndrome: A single-center retrospective study. Oncol
Lett. 16:1275–1284. 2018.PubMed/NCBI
|
|
22
|
Yu JT, Wang CY, Yang Y, Wang RC, Chang KH,
Hwang WL and Teng CL: Lymphoma-associated hemophagocytic
lymphohistiocytosis: Experience in adults from a single
institution. Ann Hematol. 92:1529–1536. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Malkan UY, Albayrak M, Yildiz A, Maral S,
Afacan Ozturk HB and Comert P: A rare case of diffuse large B-cell
lymphoma-associated hemophagocytic lymphohistiocytosis. J Oncol
Pharm Pract. 27:250–252. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim MS, Cho YU, Jang S, Seo EJ, Lee JH and
Park CJ: A case of primary bone marrow diffuse large B-cell
lymphoma presenting with fibrillar projections and hemophagocytic
lymphohistiocytosis. Ann Lab Med. 37:544–546. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li X, He Y, Wang D, Hu Y, Wang W and Huang
R: A case of diffuse large B-cell lymphoma complicated by
hemophagocytic syndrome. Clin Lab. 60:681–683. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Davidson-Moncada JK, McDuffee E and
Roschewski M: CD5+ diffuse large B-cell lymphoma with
hemophagocytosis. J Clin Oncol. 31:e76–e79. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Desai A, Saul EE, Chapman JR, Lekakis L
and Pimentel A: Adult lymphoma-associated hemophagocytic
lymphohistiocytosis: A clinical case series in a predominantly
hispanic cohort. J Med Cases. 11:256–261. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kwoun WJ, Ahn JY, Park PW, Seo YH, Kim KH,
Seo JY, Lee HT and Yoo KH: How useful is bone marrow study as an
initial investigative tool without lymph node biopsy in malignant
lymphoma?: Eleven years of experience at a single institution. J
Clin Lab Anal. 33:e228412019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chigrinova E, Mian M, Scandurra M, Greiner
TC, Chan WC, Vose JM, Inghirami G, Chiappella A, Baldini L, Ponzoni
M, et al: Diffuse large B-cell lymphoma with concordant bone marrow
involvement has peculiar genomic profile and poor clinical outcome.
Hematol Oncol. 29:38–41. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pezzella F, Munson PJ, Miller KD,
Goldstone AH and Gatter KC: The diagnosis of low-grade peripheral
B-cell neoplasms in bone marrow trephines. Br J Haematol.
108:369–376. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
de Leval L and Harris NL: Variability in
immunophenotype in diffuse large B-cell lymphoma and its clinical
relevance. Histopathology. 43:509–528. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lin P, Molina TJ, Cook JR and Swerdlow SH:
Lymphoplasmacytic lymphoma and other non-marginal zone lymphomas
with plasmacytic differentiation. Am J Clin Pathol. 136:195–210.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Boiza-Sánchez M, Manso R, Balagué O,
Chamizo C, Askari E, Salgado RN, Blas-López C, Aguirregoicoa-García
E, Menárguez J, Santonja C, et al: Lymphoplasmacytic lymphoma
associated with diffuse large B-cell lymphoma: Progression or
divergent evolution? PLoS One. 15:e02416342020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang W and Lin P: Lymphoplasmacytic
lymphoma and Waldenström macroglobulinaemia: Clinicopathological
features and differential diagnosis. Pathology. 52:6–14. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ohno T, Ueda Y, Nagai K, Takahashi T,
Konaka Y, Takamatsu T, Suzuki T, Sasada M and Uchiyama T; Kyoto
University Hematology/Oncology Study Group, : The serum cytokine
profiles of lymphoma-associated hemophagocytic syndrome: A
comparative analysis of B-cell and T-cell/natural killer cell
lymphomas. Int J Hematol. 77:286–294. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Aggarwal BB: Signalling pathways of the
TNF superfamily: A double-edged sword. Nat Rev Immunol. 3:745–756.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pękalski J, Zuk PJ, Kochańczyk M, Junkin
M, Kellogg R, Tay S and Lipniacki T: Spontaneous NF-κB activation
by autocrine TNFα signaling: A computational analysis. PLoS One.
8:e788872013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kagoya Y, Yoshimi A, Kataoka K, Nakagawa
M, Kumano K, Arai S, Kobayashi H, Saito T, Iwakura Y and Kurokawa
M: Positive feedback between NF-κB and TNF-α promotes
leukemia-initiating cell capacity. J Clin Invest. 124:528–542.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hayakawa K, Meng Y, Hiramatsu N, Kasai A,
Yao J and Kitamura M: Spontaneous activation of the NF-kappaB
signaling pathway in isolated normal glomeruli. Am J Physiol Renal
Physiol. 291:F1169–F1176. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lee TK, Denny EM, Sanghvi JC, Gaston JE,
Maynard ND, Hughey JJ and Covert MW: A noisy paracrine signal
determines the cellular NF-kappaB response to lipopolysaccharide.
Sci Signal. 2:ra652009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hashwah H, Bertram K, Stirm K, Stelling A,
Wu CT, Kasser S, Manz MG, Theocharides AP, Tzankov A and Müller A:
The IL-6 signaling complex is a critical driver, negative
prognostic factor, and therapeutic target in diffuse large B-cell
lymphoma. EMBO Mol Med. 11:e105762019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hasnain SZ: Endoplasmic reticulum and
oxidative stress in immunopathology: Understanding the crosstalk
between cellular stress and inflammation. Clin Transl Immunology.
7:e10352018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Nikesitch N, Lee JM, Ling S and Roberts
TL: Endoplasmic reticulum stress in the development of multiple
myeloma and drug resistance. Clin Transl Immunology. 7:e10072018.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang HQ, Jia L, Li YT, Farren T, Agrawal
SG and Liu FT: Increased autocrine interleukin-6 production is
significantly associated with worse clinical outcome in patients
with chronic lymphocytic leukemia. J Cell Physiol. 234:13994–14006.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Knittel G, Liedgens P, Korovkina D,
Pallasch CP and Reinhardt HC: Rewired NFκB signaling as a
potentially actionable feature of activated B-cell-like diffuse
large B-cell lymphoma. Eur J Haematol. 97:499–510. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao
Y, Sheehy P, Manning RJ, Patterson CJ, Tripsas C, et al: MYD88
L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J
Med. 367:826–833. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Maamoun H, Abdelsalam SS, Zeidan A,
Korashy HM and Agouni A: Endoplasmic reticulum stress: A critical
molecular driver of endothelial dysfunction and cardiovascular
disturbances associated with diabetes. Int J Mol Sci. 20:16582019.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Obeng EA, Carlson LM, Gutman DM,
Harrington WJ Jr, Lee KP and Boise LH: Proteasome inhibitors induce
a terminal unfolded protein response in multiple myeloma cells.
Blood. 107:4907–4916. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Grondona P, Bucher P, Schulze-Osthoff K,
Hailfinger S and Schmitt A: NF-κB activation in lymphoid
malignancies: Genetics, signaling, and targeted therapy.
Biomedicines. 6:382018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Treon SP, Xu L, Guerrera ML, Jimenez C,
Hunter ZR, Liu X, Demos M, Gustine J, Chan G, Munshi M, et al:
Genomic landscape of Waldenström macroglobulinemia and its impact
on treatment strategies. J Clin Oncol. 38:1198–1208. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Chapuy B, Stewart C, Dunford AJ, Kim J,
Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, et
al: Molecular subtypes of diffuse large B cell lymphoma are
associated with distinct pathogenic mechanisms and outcomes. Nat
Med. 24:679–690. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Visco C, Tanasi I, Quaglia FM, Ferrarini
I, Fraenza C and Krampera M: Oncogenic mutations of MYD88 and CD79B
in diffuse large B-Cell lymphoma and implications for clinical
practice. Cancers. 12:29132020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Young RM and Staudt LM: Targeting
pathological B cell receptor signalling in lymphoid malignancies.
Nat Rev Drug Discov. 12:229–243. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Vermaat JS, Somers SF, de Wreede LC, Kraan
W, de Groen RA, Schrader AM, Kerver ED, Scheepstra CG, Berenschot
H, Deenik W, et al: MYD88 mutations identify a molecular subgroup
of diffuse large B-cell lymphoma with an unfavorable prognosis.
Haematologica. 105:424–434. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Thieblemont C, Howlett S, Casasnovas RO,
Mounier N, Perrot A, Morschhauser F, Fruchart C, Daguindau N, van
Eygen K, Obéric L, et al: Lenalidomide maintenance for diffuse
large B-cell lymphoma patients responding to R-CHOP: Quality of
life, dosing, and safety results from the randomised controlled
REMARC study. Br J Haematol. 189:84–96. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Keats JJ, Fonseca R, Chesi M, Schop R,
Baker A, Chng WJ, Van Wier S, Tiedemann R, Shi CX, Sebag M, et al:
Promiscuous mutations activate the noncanonical NF-kappaB pathway
in multiple myeloma. Cancer Cell. 12:131–144. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Dunleavy K, Pittaluga S, Czuczman MS, Dave
SS, Wright G, Grant N, Shovlin M, Jaffe ES, Janik JE, Staudt LM and
Wilson WH: Differential efficacy of bortezomib plus chemotherapy
within molecular subtypes of diffuse large B-cell lymphoma. Blood.
113:6069–6076. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Davies A, Cummin TE, Barrans S, Maishman
T, Mamot C, Novak U, Caddy J, Stanton L, Kazmi-Stokes S, McMillan
A, et al: Gene-expression profiling of bortezomib added to standard
chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): An
open-label, randomised, phase 3 trial. Lancet Oncol. 20:649–662.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Tang S, Zhao C and Chen W: Aggressive
diffuse large B-cell lymphoma with hemophagocytic
lymphohistiocytosis: Report of one case. Int J Clin Exp Pathol.
13:2392–2396. 2020.PubMed/NCBI
|
|
60
|
Wu R, Deng X, Hao S and Ma L: Successful
treatment of diffuse large B-cell lymphoma with secondary
hemophagocytic lymphohistiocytosis by R-CHOP-E regimen: A case
report. J Int Med Res. 48:3000605198822332020.PubMed/NCBI
|
|
61
|
Patel R, Patel H, Mulvoy W and Kapoor S:
Diffuse large B-cell lymphoma with secondary hemophagocytic
lymphohistiocytosis presenting as acute liver failure. ACG Case Rep
J. 4:e682017. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Patel A, Vakiti A, Chilkulwar A and
Mewawalla P: Hemophagocytic lymphohistiocytosis secondary to bone
marrow only B-cell lymphoma: A very rare entity with an even rarer
presentation. J Hematol. 6:49–51. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Entezari V, Agwa E, Ruiz SJ, Lietman SA,
Silver BJ and Jegalian AG: Hemophagocytic lymphohistiocytosis
secondary to localized large B-cell lymphoma in a patient with
history of knee arthroplasty. Leuk Lymphoma. 56:1521–1523. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Kuo CY, Yeh ST, Huang CT and Lin SF:
Diffuse large B-cell lymphoma presenting with type B lactic
acidosis and hemophagocytic syndrome. Kaohsiung J Med. 30:428–429.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Wang L, Zhang XH, Zhou YL and Yin XL:
Hemophagocyte lymphohistiocytosis secondary to bilateral epididymal
diffuse large B-cell lymphoma. Indian J Hematol Blood Transfus. 30
(Suppl 1):S93–S96. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Sano T, Sakai H, Takimoto K and Ohno H:
Rituximab alone was effective for the treatment of a diffuse large
B-cell lymphoma associated with hemophagocytic syndrome. Int J Clin
Oncol. 12:59–62. 2007. View Article : Google Scholar : PubMed/NCBI
|
